Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Number of employees : 520 people.
Sales per Businesses
20162017Delta
USD (in Million)%USD (in Million)%
Rare Diseases Treatment Products0.133100%---
Collaboration and License--2.1481.8%-
Product--0.47618.2%-
Sales per Regions
20162017Delta
USD (in Million)%USD (in Million)%
United States0.133100%2.61100% +1863.91%
Managers
NameAgeSinceTitle
Emil D. Kakkis MD, PhD582010President, Chief Executive Officer & Director
Daniel G. Welch, MBA612015Non-Executive Chairman
Wladimir Hogenhuis-2018Chief Operating Officer
Shalini Sharp, MBA442012Chief Financial Officer & Executive Vice President
Dennis Karl Huang542015Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian, MD662018Chief Medical Officer & Executive Vice President
Eric Crombez, MD-2017Chief Medical Officer
Samuel C. Wadsworth, PhD--Chief Scientific Officer-Ultragenyx Gene Therapy
William E. Aliski712011Independent Director
Matthew K. Fust, MBA542014Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 57,472,474 54,170,878 94.3% 0 0.0% 94.3%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 5,856,138 11.6%
Wellington Management Co. LLP 5,274,908 10.4%
Capital Research & Management Co. (International Investors) 4,359,891 8.62%
The Vanguard Group, Inc. 3,951,864 7.81%
BlackRock Fund Advisors 3,546,199 7.01%
Fidelity Management & Research Co. 3,310,512 6.55%
Emil D. Kakkis MD, PhD 3,010,213 5.95%
T. Rowe Price Associates, Inc. 2,778,029 5.49%
SSgA Funds Management, Inc. 1,712,524 3.39%
First Trust Advisors LP 1,471,934 2.91%
Company contact information
Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato, CA 94949

Phone : +1.415.483.8800
Fax : +1.415.483.8810
Web : http://www.ultragenyx.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC31.51%3 286
GILEAD SCIENCES6.94%85 054
VERTEX PHARMACEUTICALS3.66%43 994
REGENERON PHARMACEUTICALS-16.32%33 671
GENMAB14.61%11 324
SAREPTA THERAPEUTICS INC10.73%8 961
BEIGENE LTD--.--%7 597
NEUROCRINE BIOSCIENCES, INC.11.88%7 293
BLUEBIRD BIO INC23.85%6 772
EXELIXIS, INC.3.51%6 144
PEPTIDREAM INC25.00%6 017
ARRAY BIOPHARMA INC90.11%6 007
ASCENDIS PHARMA A/S105.84%5 971
HUALAN BIOLOGICAL ENGINEERING INC--.--%5 651
ARGEN-X42.37%5 122
BIOCON LTD-15.01%4 559
SPARK THERAPEUTICS INC--.--%4 238
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-2.66%3 989
CHINA BIOLOGIC PRODUCTS HOLDINGS INC19.88%3 546
SILLAJEN INC--.--%3 313
IDORSIA LTD38.35%2 858
Connections : Ultragenyx Pharmaceutical